Y-mAbs Therapeutics, Inc.

General ticker "YMAB" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $341.7M (TTM average)

Y-mAbs Therapeutics, Inc. follows the US Stock Market performance with the rate: 10.5%.

Estimated limits based on current volatility of 0.1%: low 8.59$, high 8.60$

Factors to consider:

  • US accounted for 75.2% of revenue in the fiscal year ended 2024-12-31
  • Earnings for 6 months up through Q2 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [4.50$, 12.08$]
  • 2025-12-31 to 2026-12-31 estimated range: [3.10$, 8.72$]

Financial Metrics affecting the YMAB estimates:

  • Negative: with PPE of -12.2 at the end of fiscal year the price was very high
  • Negative: negative Operating income
  • Negative: Operating cash flow per share per price, % of -4.34 <= 0.99
  • Positive: Shareholder equity ratio, % of 76.73 > 62.64
  • Positive: Interest expense per share per price, % of 0 <= 0
  • Positive: Investing cash flow per share per price, % of 0 > -0.78
  • Positive: Industry inventory ratio change (median), % of 0 <= 0

Similar symbols

Short-term YMAB quotes

Long-term YMAB plot with estimates

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $65.27MM $84.82MM $87.69MM
Operating Expenses $160.08MM $110.49MM $118.89MM
Operating Income $-94.81MM $-25.67MM $-31.20MM
Non-Operating Income $-0.76MM $4.81MM $1.39MM
R&D Expense $91.57MM $54.22MM $48.99MM
Income(Loss) $-95.57MM $-20.87MM $-29.81MM
Taxes $0.00MM $0.56MM $-0.15MM
Profit(Loss)* $-95.57MM $-21.43MM $-29.67MM
Stockholders Equity $109.22MM $100.98MM $92.00MM
Inventory $6.70MM $5.07MM $7.21MM
Assets $141.46MM $127.87MM $119.90MM
Operating Cash Flow $-75.92MM $-27.23MM $-15.71MM
Investing Cash Flow $0.04MM $0.01MM $0.00MM
Financing Cash Flow $0.08MM $0.10MM $4.31MM
Earnings Per Share** $-2.19 $-0.49 $-0.67

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.